Clinical advantages of COMT inhibition with entacapone - A review

Journal of Neural Transmission

Volumn 111, Issue 10-11, 2004, Pages 1343-1363

  Gordin, A ^a   Kaakkola, S ^b   Teravainen H ^b  

^a Research Centre   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

COMT inhibition; Entacapone; Levodopa therapy; Parkinson's disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMANTADINE; BENSERAZIDE; CARBIDOPA; CARBIDOPA PLUS ENTACAPONE PLUS LEVODOPA; CARBIDOPA PLUS LEVODOPA; CATECHOL METHYLTRANSFERASE INHIBITOR; DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA; PLACEBO; SELEGILINE; TOLCAPONE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; BACKACHE; BIOAVAILABILITY; CONSTIPATION; DIARRHEA; DIZZINESS; DOPAMINE RELEASE; DOPAMINERGIC TRANSMISSION; DRUG ABSORPTION; DRUG EFFECT; DRUG ELIMINATION; DRUG SAFETY; DYSKINESIA; DYSTONIA; ENZYME INHIBITION; EPIGASTRIC PAIN; FATIGUE; HALLUCINATION; HUMAN; HYPOKINESIA; INSOMNIA; LIVER TOXICITY; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TREMOR; VOMITING;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; HUMANS; LEVODOPA; PARKINSON DISEASE; QUALITY OF LIFE;

EID: 7944236868     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0190-3     Document Type: Review

References (96)

1. Ahlskog JE, Muenter MD (2001) Frequency of levodopa related dyskinesias and motor fluctuations as estimated from cumulative literature. Mov Disord 16: 448-458
2. Assal F, Sphar L, Hadengue A, Rubia-Brandt A, Burkhard L, Rubia-Brandt L (1998) Tolcapone and fulminant hepatitis. Lancet 352: 958
3. Axelrod J, Tomchick R (1958) Enzymatic O-methylation of epinephrine and other catechols. J Biol Chem 233: 702-705
4. Barbeau A (1969) L-dopa therapy in Parkinson's disease: a critical review of 9 years experience. Can Med Assoc J 101: 791-800
5. Beck S, Hubble J, Reinikainen K (2002) Entacapone-induced hepatotoxicity and hepatic dysfunction. Reply to McLean and Purcell. Mov Disord 17: 1397-1399
6. Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F (1973) Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci 20: 415-455
7. Birkmayer W, Hornykiewicz O (1961) Der L-3,4-dioxyphenylalanine (DOPA) Effekt bei der Parkinson Akinese. Wien Klin Wochenschr 73: 787-788
8. Borgulya J, Brudere H, Bernauer K, Zurher G, Da Prada M (1989) Catechol-O-methyltransferase inhibiting pyrocatechol derivatives: synthesis and structure-activity studies. Helv Chim Acta 72: 952-968
9. Brooks DJ, Sagar H, and the UK-Irish Entacapone Study Group (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomised, placebo-controlled, double-blind six-month study. J Neurol Neurosurg Psychiatry 74: 1064-1072
10. Brooks DJ, Agid Y, Östergaard K, Widner H, Oertel W (2003) A new triple combination tablet is easy to initiate and provides improved symptom control in patients with Parkinson's disease. Eur J Neur 10 [Suppl 1]: P3108
11. Carlsson A (2002) Treatment of Parkinson's disease with L-dopa. The early discovery phase, and comment on current problems. J Neural Transm 109: 777-787
12. Colosimo C (1999) The rise and fall of tolcapone. J Neurol 245: 880-882
13. Cozias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. N Engl J Med 267: 374-379
14. Durif F, Devaux I, Pere J-J, Delumeau J-C, Bordeix I, on behalf of the F-01 Study Group (2001) Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 45: 111-118
15. EMEA public statement on the lifting of the suspension of the Marketing Authorisation for tolcapone (Tasmar). EMEA/11854/04
16. Fahn S (2000) The spectrum of levodopa-induced dyskinesias. Ann Neurol 47 [Suppl 1]: 2-11
17. Fenelon G, Gimenez-Roldan S, Montastruc J-L, Bermejo F, Durif F, Bordeix I, Pere JJ, Galiano L, Schadrack J (2003) Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized double-blind, multicentre study. J Neural Transm 110: 239-251
18. Gershanik O, Emre M, Bernhard G, Sauer D (2003) Efficacy and safety of levodopa patients suboptimally controlled with levodopa in Parkinson's disease with levodopa alone, in daily clinical practice. An international, multicentre, open label study. Prog Neuropsychopharmacol Biol Psychiatry 27: 963-971
19. Gordin A, Kaakkola S, Teräväinen H (2003) Position of COMT inhibition in the treatment of Parkinson's disease. Adv Neurol 91: 237-250
20. Graham JS, Henderson JM, Morris JG, Yiannikas C (1991) A comparison of standard Madopar and controlled release Madopar in Parkinson's disease. Aust NZ J Med 21: 11-15
21. Haapaniemi H, Reinikainen K, Leinonen M, Karonen T (2000) Tolerability and safety of entacapone in the treatment of Parkinson's disease. Parkinsonism Related Disord 7 [Suppl 1]: S57
22. Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A (2002) The effect of different repeated doses of entacapone on the pharmacokinetics of levodopa and on the clinical response to levodopa in Parkinson's disease. Clin Neuropharmacol 24: 150-157
23. Heikkinen H, Varhe A, Lyly V, Korpela K, Laine T, Kaakkola S (2003) New levodopa, carbidopa and entacapone combination tablets. Eur J Neurol 10 [Suppl 1]: P2141
24. Hornykiewicz O (2001) How L-dopa was discovered as a drug for Parkinson's disease 40 years ago. Wien Klin Wochenschr 113: 855-862
25. Hubble JP, Guarnieri M, Olanow CW (2003) Effects of entacapone in Parkinson's disease patients without end of dose wearing off. Neurology 60 [Suppl 1]: A289-A290
26. Hutton J, Morris J (1994) Therapeutic advantages of sustained release levodopa formulations. CNS Drugs 2: 110-119
27. Illi A, Sundberg S, Koulu M, Scheinin M, Heinävaara S, Gordin A (1994) COMT inhibition by high dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 11: 582-588
28. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A (1995) The effect of entacapone on the disposition and hemodynamic effects of intravenous isoprotanerol and epinephrine. Clin Pharmacol Ther 58: 221-227
29. Illi A, Sundberg S, Ojala-Karlsson P, Korhonen P, Scheinin M, Gordin A (1996a) Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 59: 450-457
30. Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A (1996b) Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine. Eur J Clin Pharmacol 51: 273-276
31. Jenkinson D, Fizpatrick R, Peto V (1999) Health related quality of life measurement in patients with Parkinson's disease. Pharmaco Economics 15: 157-165
32. Jenner P, Al-Barghouthy G, Smith L, Kuoppamäki M, Jackson M, Rose S (2002) Initiation of entacapone with L-dopa further improves antiparkinsonian activity and avoids dyskinesia in the MPTP primate model of Parkinson's disease. Neurology 58 [Suppl 3]: A374-A375
33. Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59: 1233-1250
34. Kaakkola S, Teräväinen H, Ahtila S, Rita H, Gordin A (1994) Effect of entacapone, a COMT inhibitor, on clinical disability and levodopa metabolism in parkinsonian patients. Neurology 44: 77-80
35. Kaakkola S, Teräväinen H, Ahtila S, Karlsson M, Naukkarinen T, Rita H, Gordin A (1995) Entacapone in combination with standard or controlled release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease. Eur J Neurol 2: 1-7
36. Karlsen KH, Larsen JP, Tandberg E, Melamed JG (1998) Quality of life measurements in patients with Parkinson's disease: a community based study. Eur J Neurol 5: 1-8
37. Karlsen KH, Tandberg E, Arlsland D, Larsen JP (2000) Health related quality of life in Parkinson's disease: a prospective longitudinal study. J Neurol Neurosurg Psychiatry 69: 584-589
38. Keränen T, Gordin A, Harjola VP, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Seppälä L, Wikberg T (1993) The effect of catechol-O-methyltransferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 16: 145-156
39. Keränen T, Gordin A, Karlsson M, Korpela K, Pentikäinen PJ, Rita H, Schultz E, Seppälä L, Wikberg T (1994) Inhibition of soluble catechol-O-methyltransferase and single dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46: 151-157
40. Koller W, Guarnieri M, Hubble J and the SELECT-TC Study Group (2004) An open-label evaluation of the tolerability and safety of the triple combination (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing off (personal communication)
41. Kuopio A-M, Anttila RJ, Helenius H, Toivoinen M, Rinne UK (2002) The quality of life in Parkinson's disease. Mov Disord 15: 216-223
42. Lang AE, Lozano AM (1998a) Parkinson's disease - first of two parts. N Engl J Med 339: 1044-1053
43. Lang AE, Lozano AM (1998b) Parkinson's disease - second of two parts. N Engl J Med 339: 1130-1143
44. Larsen JP, Worm-Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M, and the NOMESAFE Study Group (2003) Long-term efficacy and safety of entacapone in parkinsonian patients with motor fluctuations. An open study of 3 years duration. Eur J Neurol 10: 137-146
45. Lee MS, Hyoung C, Ulmanen I, Syvänen A-C, Rinne JO (2001) Genotypes of catechol-O-methyltrasferase and response to levodopa treatment in patients with Parkinson's disease. Neurosci Lett 298: 131-134
46. Lee MS, Kim HS, Cho EK, Lim JH, Rinne JO (2002) COMT genotype and effectiveness of entacapone in patients with fluctuating Parkinson's disease. Neurology 58: 564-567
47. Linna M, Taimela E, Apajasalo M, Marttila R (2002) Proballistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease. Expert Rev Pharmacoeconomic Outcomes Res 2: 91-97
48. Lyytinen J, Sovijärvi A, Kaakkola S, Gordin A, Teräväinen H (2001) The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-dopa treated patients with Parkinson's disease. Clin Neuropharmacol 24: 50-57
49. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet I: 345-349
50. McLean AJ, Purcell P (2002) Entacapone-induced hepatotoxicity and hepatic dysfunction. Mov Disord 17: 1399-1400
51. Merello M, Lees AL, Webster R, Bovingdon M, Gordin A (1994) Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 57: 186-189
52. Montastruc JL, Rascol O, Senard JM, Rascol A (1994) A randomised controlled study comparing bromocriptine to which levodopa was later added, with levodopa alone in previously untreated patients with Parkinson's disease: a five year follow up. J Neurol Neurosurg Psychiatry 57: 1034-1038
53. Männistö PT, Kaakkola S (1989) New selective COMT inhibitors: useful adjuncts for Parkinson's disease? Trends Pharmacol Sci 10: 54-56
54. Männistö PT, Kaakkola S (1990) Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson's disease. Pharmacol Toxicol 66: 317-323
55. Männistö PT, Kaakkola S, Nissinen E, Linden I-B, Pohto P (1988) Properties of novel effective and highly selective inhibitors of catechol-O-methyltransferase. Life Sci 43: 1465-1471
56. Myllylä VV, Sotaniemi KA, Illi A, Suominen K, Keränen T (1993) Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease. Eur J Clin Pharmacol 45: 419-423
57. Myllylä VV, Kultalahti E-R, Haapaniemi H, Leinonen M, and the Filomen Study Group (2001) Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 28: 53-60
58. Myllylä V, Haapaniemi T, Hartikainen P, Nuutinen J, Rissanen A, Kuopio AM, Jolma T, Satomaa O, Kinnunen E, Kaakkola S (2003) First experience of the new triple combination of levodopa/carbidopa/entacapone in the treatment of Parkinson's disease. Eur J Neurol 10 [Suppl 1]: P2140
59. Nissinen E, Linden IB, Schultz E, Pohto P (1992) Biochemical and pharmacological properties of a peripherally acting catechol-O-methyltransferase inhibitor entacapone. Naunyn Schmiedebergs Arch Pharmacol 346: 262-266
60. Nuijten JC, van Iperen P, Palmer C, van Hilten JB, Snyder E (2001) Cost-effectiviness analysis of entacapone in Parkinson's disease: a Markov process analysis. Value Health 4: 316-328
61. Nutt JG (1998) Catechol-O-methyltransferase inhibitors for treatment of Parkinson's disease. Lancet 351: 1221-1222
62. Nutt JG (2000) Effect of COMT inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 55 [Suppl 4]: S33-S37
63. Nutt JG, Woodward WR, Beckner RM, Berggren K, Carter JH, Gancher ST, Hammerstad JT, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44: 913-919
64. Nyholm D, Lennernaes H, Gomes-Trolin C, Aquilonius SM (2002) Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations. Clin Neuropharmacol 25: 89-96
65. Obeso JA, Olanow CW (1997) Dopamine agonists in early Parkinson's disease. In: Olanow CW, Obeso JA (eds) Beyond the decade of the brain, vol 2. Wells Medical Ltd, Tunbridge Wells, pp 11-35
66. Palmer C, Nuijten JC, Schmier J, Subedi P, Snyder E (2002) Cost-effectivines of treatment of Parkinson's disease with entacapone in the United States. Pharmaco Economics 20: 617-628
67. Papavasiliou PS, Cotzias GC, Duby SE, Steck AJ, Fehling C, Bell MA (1972) Levodopa in parkinsonism: potentiation of central effects with a peripheral inhibitor. N Engl J Med 286: 8-14
68. Parkinson Study Group (1996) Impact on deprenyl and tocopherol treatment on Parkinson's disease in the DATATOP patients requiring levodopa. Ann Neurol 39: 37-45
69. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 42: 747-755
70. Parkinson Study Group (2000) Pramipexole vs. levodopa as initial treatment for Parkinson's disease. A randomized controlled study. JAMA 248: 1931-1938
71. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R (1995) The development and validation of a short measure functioning and well being for individuals with Parkinson's disease. Qual Life Res 4: 241-248
72. Peto V, Jenkinson C, Fitzpatrick R (2001) Determining minimally important difference for the PDQ-39 Parkinson's disease questionnaire. Age Ageing 30: 299-302
73. Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A (2000) The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry 68: 589-594
74. Poewe W, Deuschl G, Gordin A, Kultalahti E-R, Leinonen M, and the Celomen Study Group (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a six-month randomised placebo-controlled, double-blind study in Germany and Austria. Acta Neurol Scand 105: 245-255
75. Poewe W, Deuschl G, Kultalahti E-R, Reinikainen K, Leinonen M (2003) Entacapone is safe in long-term use in Parkinson's disease. An Austrian-German open two-year study. Eur J Neurol 10 [Suppl 1]: P3102
76. Rascol O, Brooks DJ, Korczyn AD, De Deyen PP, Clarke C, Lang A (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 342: 1484-1491
77. Reinikainen K, Karonen T, Haapaniemi H, Ahtinen H, Kaakkola S (2001) No indication for interactions between entacapone and antidepressants. Parkinsonism Related Disord 7 [Suppl 1]: S67
78. Riederer P, Wuketich S (1976) Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm 38: 277-301
79. Rinne UK, Bracho F, Chousa C, Dupont E, Gershanik O, Masso JFM, Montastruc JL, Marsden CD, and the PKD009 Study Group (1998) Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Drugs 55 [Suppl 1]: 23-30
80. Rinne UK, Larsen JP, Siden Å, Worm-Petersen J, and the Nomecomt Study Group (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 51: 1309-1314
81. Rouru J, Gordin A, Huupponen R, Huhtala S, Savontaus E, Korpela K, Reinikainen K, Scheinin M (1999) Pharmacokinetics of oral entacapone after frequent multiple dosing and effects of levodopa disposition. Eur J Clin Pharmacol 55: 461-467
82. Ruottinen HM, Rinne UK (1996a) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjunct to levodopa therapy in advanced Parkinson's disease. Clin Neuropharmacol 19: 283-296
83. Ruottinen HM, Rinne UK (1996b) Effect of one month's treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 19: 222-233
84. Ruottinen HM, Rinne UK (1996c) Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 60: 36-40
85. 18F)fluorodopa accumulation after combined inhibition of peripheral catechol-O- methyltransferase and monoamoine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. Synapse 27: 336-346
86. Schrag A, Quinn N (2000a) Dyskinesias and motor fluctuations in Parkinson's disease: a community-based study. Brain 123: 2297-2305
87. Schrag A, Jahanshahi M, Quinn N (2000b) How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15: 1112-1118
88. Schrag A, Jahanshahi M, Quinn N (2000c) What contributes to quality of life in patients with Parkinson's disease? J Neurol Neurosurg Psychiatry 59: 308-312
89. Sonnenberg FA, Beck CR (1993) Markov models in medical decision making. A practical guide. Med Decis Making 13: 322-332
90. Stocchi FA, Vacca L, Onofrj M (2003) Are there clinically significant differences between dopamine agonists? Adv Neurol 91: 359-266
91. Syvanen AC, Tilgman C, Rinne JO, Ulmanen I (1997) Genetic polymorphism of catechol-O-methyltransferase (COMT): correlation of genotype with individual variation of S-COMT activity comparison of the allele frequencies in the normal population and parkinsonian patients in Finland. Pharmacogenetics 7: 65-71
92. Troconiz IF, Naukkarinen TH, Ruottinen HM, Rinne UK, Gordin A, Karlsson MO (1998) Population pharmacodynamic modelling of levodopa in patients with Parkinson's disease receiving entacapone. Clin Pharmacol Ther 64: 106-116
93. Waters C, Heikkinen H, Holopainen A, Leinonen M, Gordin A (2003) Entacapone is safe in long-term use in patients with Parkinson's disease. A North American open 3-year safety and 1-year efficacy study. Eur J Neurol 10 [Suppl 1]: P3105
94. Widner H (2003) Strategies to modify levodopa treatment. Adv Neurol 91: 229-236
95. Yeh KC, August TF, Bush DF, Lasserer KL, Musson DG, Schwatz S, Smith ME, Titus DC (1989) Pharmacokinetics and bioavailability of Sinemet CR™: a summary of human studies. Neurology 39 [Suppl 2]: 25-38
96. Zijlmans JCM, Debilly B, Rascol O, Lees AJ, Durif F (2004) Safety of entacapone and apomorphine co-administration in levodopa-treated Parkinson's disease patients; results of pharmacokinetics, pharmacodynamics, a multicenter, double-blind, placebo controlled, cross-over study. Mov Disord (in press)